Get started
Author

Elena A. Orlova-Morozova

Observed names: E A Orlova-Morozova, E Orlova-Morozova, E Orlova‐Morozova, E. A. Orlova-Morozova, E.A. Orlova-Morozova, Elena Orlova-Morozova, Elena Orlova‐Morozova
Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Russian Academy of Sciences, Sechenov University, Central Clinical Hospital and Polyclinic, Pirogov Russian National Research Medical University, Centre for Prevention and Control of AIDS and Infectious Diseases, Regional Center for Prevention and Control of AIDS and Infectious Diseases, Ministry of Health of the Russian Federation
ORCID: 0000-0003-2495-6501
Observed ORCID: 0000-0003-2495-6501
OpenAlex ID: A5067500511
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
2018 · Jean-Michel Molina, Kathleen Squires, et al. · The Lancet HIV · 155
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
2019 · Jean-Michel Molina, Kathleen Squires, et al. · The Lancet HIV · 100
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
2023 · Chloe Orkin, Jean-Michel Molina, et al. · The Lancet HIV · 38
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
2017 · Pedro Cahn, Richard Kaplan, et al. · The Lancet HIV · 35
PDF
Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
2018 · A. V. Kravchenko, E. A. Orlova-Morozova, et al. · Journal Infectology · 11
PDF
Features of Tat Protein in HIV-1 Sub-Subtype A6 Variants Circulating in the Moscow Region, Russia
2023 · Anna Kuznetsova, Kristina Kim, et al. · Viruses · 10
PDF
Ledipasvir–Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection
2017 · Vasily Isakov, Natalia Gankina, et al. · Clinical Drug Investigation · 9
Variability of VPU protein in HIV-1 sub-subtype A6 in patients with different stages of HIV infection
2024 · A. A. Antonova, A. V. Lebedev, et al. · HIV Infection and Immunosuppressive Disorders · 4
PDF
Genetic diversity of Vif protein in human immunodeficiency virus type 1 variants (Retroviridae: Orthoretrovirinae: Lentivirus: Human immunodeficiency virus-1) that circulated in the Moscow region in 2019–2020
2025 · Anastasiia A. Antonova, Larisa A. Protasova, et al. · Problems of Virology · 3
PDF
Real‐world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV ‐1 sub‐subtype A6 harbouring the L74I mutation
2025 · Elena Orlova‐Morozova, Dmitry Kireev, et al. · HIV Medicine · 2
Evaluation of Clinical and Economic Efficiency and Impact of Mass Fluorography Screening on Tuberculosis Epidemiological Rates in Four Federal Districts of the Russian Federation with Different Levels of Population Coverage with Mass Fluorography Screening
2023 · E. O. Peretsmanas, E. A. Orlova-Morozova, et al. · Tuberculosis and lung diseases · 2
PDF
Switching to dual therapy after 24 weeks of the triple therapy of HIV infection: efficacy and safety
2021 · E.I. Veselova, G.A. Kaminskiy, et al. · Infectious diseases News Opinions Training · 2
PDF
Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with tenofovir/emtricitabine – multicenter comparative trial vs efavirenz in naїve HIV patients
2017 · A.V. Kravchenko, E.A. Orlova-Morozova, et al. · Infekcionnye bolezni · 2
Nef HIV-1 (Retroviridae: Orthoretrovirinae: Lentivirus: Human immunodeficiency virus-1), multifunctional protein: features of genetic virus variants circulating in Russia
2025 · Anna I. Kuznetsova, Anastasiia A. Antonova, et al. · Problems of Virology · 1
PDF
Vpr, accessory protein of human immunodeficiency virus type 1 (Retroviridae: Orthoretrovirinae: Lentivirus: Human immunodeficiency virus-1): features of genetic variants of the virus circulating in the Moscow region in 2019–2020
2025 · Anna I. Kuznetsova, Anastasiia A. Antonova, et al. · Problems of Virology · 1
PDF
Variability of Rev protein in HIV-1 sub-subtype A6 in patients with different stages of HIV infection
2024 · A. I. Kuznetsova, K. V. Kim, et al. · HIV Infection and Immunosuppressive Disorders · 1
PDF
Treatment interruption after delivery in HIV‐infected women without HAART indications is not safe if initial CD4+ count is less than 700 cells/mm3
2012 · G Kaminskiy, E Orlova‐Morozova, et al. · Journal of the International AIDS Society · 1
Multicenter epidemiological study to describe prevalence of advanced stage disease among newly diagnosed HIV‐infected patients in the Russian Federation
2012 · A Pronin, E Orlova‐Morozova, et al. · Journal of the International AIDS Society · 1
PDF
Is this atherosclerosis in patients with HIV? Data received by OCT
2021 · N M Efendieva, O P Shevchenko, et al. · European Heart Journal
The features of atherosclerosis in HIV-infected patients by optical coherence tomography.
2021 · N.M. Efendieva, I.G. Nikitin, et al. · Atherosclerosis
Correction to: Ledipasvir–Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection
2021 · Vasily Isakov, Natalia Gankina, et al. · Clinical Drug Investigation
PDF
The evolution of attitude to participation in clinical trials of anti-HIV/AIDS vaccines in population and development of approaches to formation of volunteers cohorts
2015 · E. V Jukova, Жукова Е. В, et al. · Sociology of Medicine
Эволюция отношения к участию в клинических испытаниях анти-ВИЧ/СПИД-вакцин в популяции и развитие подходов к формированию когорт добровольцев
2015 · Eugenia Zhukova, N. N. Lebedeva, et al. · Sociology of Medicine
Interrelation of immune system individual features and hiv infection development after scheduled interruption of antiretroviral theraty in HIV infected pregnant women
2012 · E A Orlova-Morozova, A Ju Pronin, et al. · Russian Journal of Allergy
Pregnancy and treatment interruption enhances progression of HIV-infection if initial CD4+ T-lymphocyte count is less than 700 cells/mm3
2012 · E Orlova-Morozova, A Pronin, et al. · Journal of the International AIDS Society
PDF
Works count: 31
Citation count: 378
H-index: 7
I10-index: 6
Year
Topic
Type